Use of Cyclo-HisPro (CHP) for lowering blood pressure
New uses of Cyclo-HisPro (CHP) or a salt thereof for lowering blood pressure are disclosed. More specifically, the present invention relates to a pharmaceutical composition for lowering blood pressure, containing CHP or a salt thereof, and a functional health food composition containing CHP or a salt thereof; a method for lowering blood pressure using CHP or a salt thereof; a use of CHP or a salt thereof in the manufacture of antihypertensive agents; a pharmaceutical composition or a functional health food, for preventing or treating hypertension or complications thereof, containing CHP or a salt thereof; a method for preventing or treating hypertension or complications thereof by using CHP or a salt thereof; and a use of CHP or a salt thereof in the manufacture of a medicament for preventing or treating hypertension or complications thereof.
1 . A method for lowering blood pressure by relaxing blood vessels in a subject having essential hypertension or secondary hypertension caused by kidney disease or diabetes, comprising administering a composition consisting of an effective amount of Cyclo-HisPro or a pharmaceutically acceptable salt thereof as a sole active ingredient, or an effective amount of Cyclo-HisPro or a pharmaceutically acceptable salt thereof as a sole active ingredient and a pharmaceutically acceptable carrier to the subject.
2 . The method of claim 1 , wherein the Cyclo-HisPro or pharmaceutically acceptable salt thereof exhibits a blood pressure lowering effect in vascular endothelial cells through at least one activity selected from the group consisting of a) to e) below:
a) a decrease in the expression of angiotensin II type I receptor gene or protein;
b) an increase in the expression of angiotensin II type II receptor gene or protein;
c) an increase in the expression of VE-cadherin gene or protein;
d) an increase in the expression of eNOS gene or protein; and
e) increased NO production.
3 . A method for treating hypertension by relaxing blood vessels in a subject having essential hypertension or secondary hypertension caused by kidney disease or diabetes, comprising administering a composition consisting of an effective amount of Cyclo-HisPro or a pharmaceutically acceptable salt thereof as a sole active ingredient, or an effective amount of Cyclo-HisPro or a pharmaceutically acceptable salt thereof as a sole active ingredient and a pharmaceutically acceptable carrier to the subject.